High-grade gliomas (HGGs) are aggressive tumors known for their poor prognosis. Despite research into its molecular and clinical aspects, current management minimally impacts survival. It is unclear whether combining temozolomide (TMZ) with metformin (MET) could enhance survival in this population. A systematic search on PubMed, Embase, and Cochrane Library databases was conducted for studies comparing TMZ+MET versus TMZ alone for HGG. The outcomes of interest were overall survival, progression-free survival, and subgroup analysis with O6-methylguanine-DNA methyltransferase and patients with diabetes. The analysis comprised outcomes reported as hazard ratios (HRs) and odds ratios with corresponding 95% confidence intervals (CIs) as all the outcomes are continuous. A significance level of P < 0.05 was considered statistically significant. Heterogeneity was assessed using the I2 statistic with P values inferior to 0.10, and I2 > 25% were considered significant for heterogeneity. The random effects model was employed for all outcomes. Ten studies were included, comprising 3623 patients, of which 346 (9.5%) were assigned for TMZ+MET. The TMZ+MET group was associated with a significant reduction in mortality rates when compared to the TMZ alone group (HR 0.74; 95% CI 0.59, 0.93; P < 0.01; I2 29%). There was no significant difference between groups for progression-free survival (HR 0.87; 95% CI 0.68-1.12; P = 0.29). In a subgroup analysis restricted to patients who received TMZ+MET, the diabetic subgroup had a significantly higher mortality rate than the normoglycemic subgroup (odds ratio 1.25; 95% CI 1.10, 1.41; P < 0.01; I2 79%). Our results showed that patients who received TMZ+MET had a significantly higher overall survival than patients who received TMZ alone. These findings support the use of MET along with TMZ for the treatment of HGGs.
Study Design: Systematic review and meta-analysis. Objective: Direct head-to-head comparison of machine learning models aiming to predict outcomes in Anterior Cervical Discectomy and Fusion (ACDF) is necessary because existing studies typically evaluate algorithms in isolation, using heterogeneous datasets, features, and performance metrics, which limits interpretability and prevents meaningful comparison of predictive performance. Methods: We conducted a systematic review and meta-analysis according to PRISMA guidelines, searching PubMed, Embase, Web of Science and Cochrane through December 2024. We identified 26 studies (n = 443 445 patients) that developed ML models for ACDF outcomes. Algorithms were categorized into five classes by taxonomy: Logistic regression, tree-based, boosting ensembles, kernel methods and NNs. Pooled ML models’ AUCs and accuracy were extracted and estimated via random-effects inverse-variance model. Results: Overall discrimination ranged from 0.59 for major complications to 0.81 for adjacent-level disease. Logistic regression led in predicting unfavorable discharge (AUC 0.76), readmission/reintervention (0.68) and cost of care (0.83). Boosting ensembles excelled in predicting thromboembolic events (AUC 0.74; 0.68-0.80; P < 0.0001). Neural networks achieved the highest discrimination for opioid prescription (AUC 0.80; 0.75-0.85; P = 0.02) and adjacent-level disease (AUC 0.81; 0.72-0.91; P < 0.01). Kernel methods delivered an exceptional AUC of 0.97 (0.96-0.97) for adjacent-level fusion but underperformed for other outcomes (AUC 0.43-0.49). Decision-tree and mixed-ensemble approaches demonstrated intermediate performance for various outcomes (AUC range 0.54-0.75). Conclusion: Logistic regression and gradient-boosting models offer robust, generalizable discrimination across diverse ACDF outcomes. Neural networks and kernel methods showed endpoint-specific strengths. These data support prospective validation and rapid integration of ML-driven risk calculators into perioperative workflows.